Search Results
Apr 09, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Horizon Technology Finance Corporation - HRZN
action]On March 3, 2026, Horizon announced its fourth quarter and full year 2025 financial results. Among other items, Horizon reported net investment income of $0.18 per share for the quarter, a decrease from $0.32 per share from the previous quarter and $0.27 per share from the same period
More news about: Pomerantz LLP
Apr 09, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Yiren Digital Ltd. - YRD
and significantly below previously issued guidance of RMB 1.4 billion to RMB 1.6 billion. Yiren also reported a net loss of approximately RMB 882.2 million for the quarter, compared to net income of approximately RMB 331.4 million in the prior-year period. Yiren further disclosed that its provision
More news about: Pomerantz LLP
Apr 09, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Camping World Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines - CWH
objectives to structurally improve [its] turnover rates" creating gross margin headwinds into 2026. The Company reported financial results, including that "net loss was $(109.1) million for the fourth quarter of 2025, an increased loss of $49.6 million, or 83.3%," "adjusted EBITDA was $(26.2) million, an increased
More news about: Pomerantz LLP
Apr 09, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of The Vita Coco Company, Inc. - COCO
other allegations, the report alleged that Vita Coco was set to lose a key contract with Costco that represents roughly 25% of Vita Coco's net sales. The report also claimed that Vita Coco is facing internal operational issues including supply chain mismanagement, related-party transactions,
More news about: Pomerantz LLP
Apr 09, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RH - RH
year 2025 financial results. Among other items, the Company reported fourth quarter revenue growth of approximately 3.7%. RH further disclosed that its net revenues were negatively impacted by approximately $30 million due to "higher than anticipated backorder and special-order balances" tied to tariff-related
More news about: Pomerantz LLP
Apr 09, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Victoria's Secret & Co. - VSCO
Victoria's Secret reported its 2025 fourth quarter and full year financial results. Among other items, the Company reported a 4.7% decline in unadjusted net income. Victoria's Secret also disclosed that it had initiated a strategic review of the personal styling service DailyLook, a non-core asset acquired
More news about: Pomerantz LLP
Apr 09, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM
acknowledged that "a portion of the scripts were not being reimbursed and therefore, hit our co-pay assistance program," while also stating that gross-to-net performance remained "within line and expectation" and that the demand-to-revenue dynamic was "progressing as expected." On this news, Journey's
More news about: Pomerantz LLP
Apr 09, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in NuScale Power Corporation of Class Action Lawsuit and Upcoming Deadlines - SMR
plants to provide the Tennessee Valley Authority ("TVA") with up to six gigawatts of new nuclear power generation. As a result, NuScale's quarterly net loss skyrocketed to $532 million, up from $46 million in the prior year period. During a corresponding conference call, analysts pressed NuScale management
More news about: Pomerantz LLP
Apr 09, 2026, 10:00 ET HealthWell Foundation to Moderate Panel and Exhibit at Asembia's AXS26 Summit
the HealthWell FoundationA nationally recognized, independent non-profit organization founded in 2003, the HealthWell Foundation has served as a safety net across 100 disease areas for more than 1.3 million underinsured patients. Since its inception, HealthWell has provided over $5.2 billion in financial
More news about: HealthWell Foundation
Apr 09, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Gemini Space Station, Inc. and Certain Officers - GEMI
Officer. The Company also offered "preliminary unaudited estimates" of its financial results for the fiscal year ended December 31, 2025, including net revenue of $165 million to $175 million and operating expenses of $520 million to $530 million, an increase of approximately 40% from the previous fiscal
More news about: Pomerantz LLP
Apr 09, 2026, 09:40 ET $100Billion+ Drone Services Boom Fuels Rapid Rise of Drone-as-a-Service
of approximately $150.0 million from the Offering, before deducting placement agent fees and other related expenses. The Company intends to use the net proceeds from the Offering to acquire additional inventory, for working capital needs, and for general corporate purposes.DISCLAIMER: MarketNewsUpdates.com
More news about: Market News Updates
Apr 09, 2026, 09:27 ET Ten Novelis Plants Achieve New Level of Manufacturing Maturity
customers in the aerospace, automotive, beverage can and specialties industries throughout North America, Europe, Asia and South America. Novelis had net sales of $17.1 billion in fiscal year 2025. Novelis is a subsidiary of Hindalco Industries Limited, an industry leader in aluminum and copper, and the
More news about: Novelis Inc.
Apr 09, 2026, 09:07 ET CB&I Completes Acquisition of Petrofac Asset Solutions Business
assets we support, and deliver even greater value to customers around the world."The sale has been agreed on a debt-free cash-free basis. The net proceeds from the transaction will be distributed to secured creditors in accordance with the intercreditor agreement entered between Petrofac and secured
More news about: CB&I STS Delaware LLC
Apr 09, 2026, 09:00 ET Gan & Lee Pharmaceuticals Signs Exclusive License Agreement with JW Pharmaceutical, the Leading South Korean Pharma, to Advance the Global Commercialization of the Innovative GLP-1 Receptor Agonist Bofanglutide
approvals, and commercialization achievements. Following the product's commercial launch, Gan & Lee will also receive tiered royalties based on net sales. The total potential transaction value reaches up to USD 81.1 million (excluding royalties).This collaboration marks the third overseas
More news about: Gan & Lee Pharmaceuticals
Apr 09, 2026, 08:20 ET Standard & Poor's Global Ratings (S&P) Affirms Ecopetrol's Stand‑Alone Credit Profile and Revises Its Global Credit Rating
2.5% expectation. This highlights the government's significant influence over Ecopetrol's cash flow, as dividends consistently represent 40%-60% of net income. The government's continued tendency to maximize dividend payouts, coupled with its ongoing fiscal challenges, raises the possibility of constraints
More news about: Ecopetrol S.A.
Apr 09, 2026, 08:14 ET Chobani Announces $775 Million Private Offering of Senior Notes
Chobani intends to use the net proceeds from the offering to pay a dividend, and repay its promissory note (including accrued interest), to Chobani Parent, LLC ("Chobani Parent"),
More news about: Chobani, LLC
Apr 09, 2026, 08:00 ET Spring Health Data Reveals a "Silent Burnout" Crisis: Mental Health Leaves Surge as Employees Quietly Disengage
through one integrated system. Independently validated by JAMA Network Open and the Validation Institute for achieving meaningful clinical outcomes and net savings, the platform delivers personalized mental health support, including self-guided tools, coaching, therapy, medication management, and specialty
More news about: Spring Health
Apr 09, 2026, 08:00 ET Eisai to Present the Latest Data on Real-World Treatment with Lecanemab and Supporting a Standardized Framework for Treating Early Alzheimer's Disease at the 78th American Academy of Neurology's Annual Meeting
Surveillance Study of Lecanemab Treatment for Alzheimer's Disease in Real-world Clinical Practice Using Alzheimer's Network for Treatment and Diagnostics (ALZ-NET) RegistryPoster Session 1
More news about: Eisai Inc.
Apr 09, 2026, 06:18 ET METLEN Energy & Metals: Risultati Finanziari 2025
ed EBITDA pari a €753 milioni, con un utile netto di €314 milioni. L'indebitamento netto rettificato si è attestato a €2,10 miliardi, con un rapporto Net Debt/EBITDA di 3,1x, riflettendo una solida resilienza finanziaria. METLEN è valutata dalle principali agenzie internazionali di sostenibilità ed ESG,
More news about: METLEN Energy & Metals PLC
Apr 09, 2026, 06:13 ET La Caisse et Prologis lancent une coentreprise logistique paneuropéenne
actifs dans les grands marchés financiers, en placements privés, en infrastructures, en immobilier et en crédit privé. Au 31 décembre 2025, l'actif net de La Caisse s'élevait à 517 G$ CA. Pour en savoir plus, visitez le site
More news about: La Caisse; Prologis
Apr 09, 2026, 06:01 ET La Caisse and Prologis Launch Pan-European Logistics Joint Venture
group, we're active in the major financial markets, private equity, infrastructure, real estate and private credit. As at December 31, 2025, La Caisse's net assets totalled CAD 517 billion. For more information, visit
More news about: La Caisse
Apr 09, 2026, 06:00 ET Oppenheimer Adds David Fleming to Private Client Division Leadership Team
for both the branch and the broader community."Guidi brings more than 26 years of experience providing financial and business advice to high-net-worth clients and senior executives at leading firms, including Rockefeller Capital Management, Deutsche Bank, and Robertson Stephens. He earned his
More news about: Oppenheimer & Co. Inc.
Apr 09, 2026, 06:00 ET West to Host First-Quarter 2026 Conference Call
over 41 billion components and devices each year.Headquartered in Exton, Pennsylvania, West in its fiscal year 2025 generated $3.07 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included in the Standard & Poor's 500 index. For more information, visit
More news about: West Pharmaceutical Services, Inc.
Apr 09, 2026, 05:00 ET METLEN Energy & Metals: 2025 Financial Results
FTSE 100 Index. In 2025, METLEN reported consolidated revenue of €7.11 billion and EBITDA of €753 million with net profit of €314 million. Adjusted net debt stood at €2.10 billion, with a Net Debt/EBITDA ratio of 3.1x, reflecting strong financial resilience. METLEN is rated by leading international sustainability
More news about: METLEN Energy & Metals PLC
Apr 09, 2026, 05:00 ET ATFX Connect Q2 2026 Institutional Edge: How Institutions Find Opportunities in Turbulent Markets
in Spot FX, NDFs, indices, Commodities and Precious metals to a wide range of institutional clients from hedge funds, Tier 1 and regional banks, high net worth investors, asset managers, family offices and other brokers. ATFX Connect's liquidity pool is constructed from Tier 1 banks and non-bank
More news about: ATFX Connect